ARCHIVES

Costs of Rosenberg Regimen Could Hinder cooperative Group Trials

This article is from The Cancer Letter archive.

Vol. 12 No. 01 | January 3, 1986

Download PDF Visit The Full Archive

Related Articles

ASCO President Swain: “Shattering Impact on Cancer Enterprise”

February 15, 2013

News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements

January 27, 2012

Computer Learning May Help Women In Treatment Decision

October 30, 2009

DCBD Board Approved Concepts For New Grants In Cytogenetics Solid Tumor Diagnoses

December 13, 1984

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

April 9, 2010

Arizona Cancer Center Convinces State To Set Lower Limits For Aflatoxin

February 23, 1979